{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:02:36Z","timestamp":1791414156743,"version":"4.3.3"},"reference-count":28,"publisher":"American Society for Microbiology","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"HHS | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI113266"],"award-info":[{"award-number":["R01 AI113266"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>\n                    Rifampin (RIF) plus clarithromycin (CLR) for 8 weeks is now the standard of care for Buruli ulcer (BU) treatment, but CLR may not be an ideal companion for rifamycins due to bidirectional drug-drug interactions. The oxazolidinone linezolid (LZD) was previously shown to be active against\n                    <jats:named-content content-type=\"genus-species\">Mycobacterium ulcerans<\/jats:named-content>\n                    infection in mice but has dose- and duration-dependent toxicity in humans.\n                  <\/jats:p>","DOI":"10.1128\/aac.02171-18","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T06:08:13Z","timestamp":1545026893000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":13,"title":["Oxazolidinones Can Replace Clarithromycin in Combination with Rifampin in a Mouse Model of Buruli Ulcer"],"prefix":"10.1128","volume":"63","author":[{"given":"Deepak V.","family":"Almeida","sequence":"first","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till F.","family":"Omansen","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA"},{"name":"Infectious Diseases Unit, Department of Internal Medicine, University of Groningen, Groningen, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Si-Yang","family":"Li","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Lee","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacques H.","family":"Grosset","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Converse","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L.","family":"Nuermberger","sequence":"additional","affiliation":[{"name":"Center for Tuberculosis Research, Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02165-13"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.2217\/fmb.11.101"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)61962-0"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002739"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/imj.13511"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/171.3.747"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201206-1088OC"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201204-0682OC"},{"key":"e_1_3_3_12_2","unstructured":"Reference deleted."},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00052-06"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00022912"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01179-10"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03509-14"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012118.pub2"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00099-10"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1300\/J100v02n02_02"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0094462"},{"key":"e_1_3_3_21_2","unstructured":"World Health Organization. 2018. Rapid Communication: Key changes to treatment of multidrug- and rifampicin-resistant tuberculosis (MDR\/RR-TB). World Health Organization Geneva Switzerland."},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1201964"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtld.16.0113"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0006728"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1177\/0091270010366445"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00247-07"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029774"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002598"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01691-15"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.46.10.3193-3196.2002"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.44.9.2367-2372.2000"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02171-18","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02171-18","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T16:29:57Z","timestamp":1645460997000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02171-18"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1128\/AAC.02171-18"],"URL":"https:\/\/doi.org\/10.1128\/aac.02171-18","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"2018-10-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-07","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e02171-18"}}